These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 27522495)
1. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study. Paldor I; Drummond KJ; Kaye AH J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495 [TBL] [Abstract][Full Text] [Related]
2. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors. Paldor I; Pearce FC; Drummond KJ; Kaye AH J Clin Neurosci; 2016 Dec; 34():128-132. PubMed ID: 27593971 [TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia. Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544 [TBL] [Abstract][Full Text] [Related]
4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
5. Cystic glioblastoma: an evaluation of IDH1 status and prognosis. Sarmiento JM; Nuño M; Ortega A; Mukherjee D; Fan X; Black KL; Patil CG Neurosurgery; 2014 Jan; 74(1):71-5: discussion 75-6. PubMed ID: 24089051 [TBL] [Abstract][Full Text] [Related]
6. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma. Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme. Khan I; Waqas M; Shamim MS J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382 [TBL] [Abstract][Full Text] [Related]
8. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review]. de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445 [TBL] [Abstract][Full Text] [Related]
9. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)]. Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384 [TBL] [Abstract][Full Text] [Related]
10. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284 [TBL] [Abstract][Full Text] [Related]
11. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
12. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712 [TBL] [Abstract][Full Text] [Related]
13. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations? Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296 [TBL] [Abstract][Full Text] [Related]
14. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071 [TBL] [Abstract][Full Text] [Related]
15. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165 [TBL] [Abstract][Full Text] [Related]
16. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544 [TBL] [Abstract][Full Text] [Related]
17. Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. Ha SY; Kang SY; Do IG; Suh YL J Neurooncol; 2013 May; 112(3):439-48. PubMed ID: 23412777 [TBL] [Abstract][Full Text] [Related]
18. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor. Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929 [TBL] [Abstract][Full Text] [Related]
19. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Wefel JS; Noll KR; Rao G; Cahill DP Neuro Oncol; 2016 Dec; 18(12):1656-1663. PubMed ID: 27576872 [TBL] [Abstract][Full Text] [Related]
20. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma. Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]